Title:A Mini-Review on Cardiovascular and Hematological Complications of COVID-19
Volume: 2
Issue: 2
Author(s): Moein Masjedi*Pegah Jafari
Affiliation:
- Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71886,Iran
Keywords:
Cardiovascular complications, hematological complications, COVID-19, SARS-CoV-2, C-reactive protein, thromboembolic
events.
Abstract:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is named as
the coronavirus disease of 2019 (COVID-19). Patients with SARS-CoV-2 infection experience a wide
range of symptoms and they are at the risk of various systemic complications. Besides the pulmonary
complications, COVID-19 cases may develop cardiovascular and hematological complications. This
study aimed to review the most important hematological and cardiovascular complications caused by
SARS-CoV-2 infection.
Methods: The English databases, including Pubmed, ScienceDirect, Cochrane Library, Scopus, and
Google Scholar, were searched. The published papers were selected and reviewed based on the subject
of this study.
Results: The review of the literature showed that several cardiovascular complications related to
COVID-19, including acute myocardial infarction, cardiomyopathy, acute heart failure, and venous
thromboembolic events due to coagulation abnormalities, have been reported. COVID-19 associated
hematological complications include elevated levels of hematological factors including C-reactive protein,
lactate dehydrogenase, procalcitonin, and ferritin. Furthermore, the levels of blood cells, including
lymphocytes and thrombocytes, can be reduced.
Conclusion: This study reviewed COVID-19-associated cardiovascular and hematopoietic complications.
In conclusion, the patients may experience a wide range of cardiovascular and hematological issues
during the illness. These complications are often associated with the need for ICU support and care
which imposes further costs to the healthcare system. So the healthcare team must consider the possible
complications when treating COVID-19 patients to reduce the treatment costs and mortality of patients.
